Alberta health minister signs onto federal deal for rare disease drugs
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 05/12/2024 (367 days ago), so information in it may no longer be current.
EDMONTON – Alberta Health Minister Adriana LaGrange has signed a deal with her federal counterpart to expand access to medication for people with rare diseases.
LaGrange joined federal Health Minister Mark Holland in Edmonton to announce millions in spending on both emerging and proven drugs, as well as on diagnostics and screening.
The drugs include Poteligeo for treating Sézary syndrome, Oxlumo for hyperoxaluria type 1 and Epkinly for large B-cell lymphoma.
LaGrange says the move will help support Albertans living with rare diseases and open the door to potentially life-changing treatments.
Holland says the deal is a step toward building a stronger public health system for Albertans and aims to give Albertans with rare diseases the “best health outcomes possible.”
Alberta is the third province behind B.C. and Newfoundland and Labrador to sign onto a federal deal under the National Strategy for Drugs for Rare Diseases.
This report by The Canadian Press was first published Dec. 5, 2024.